

Markus Hinder

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8279299/markus-hinder-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33
papers

569
citations

12
h-index

23
g-index

36
ext. papers

745
ext. citations

6.2
avg, IF

4
L-index

#	Paper	IF	Citations
33	Evaluation of cardiac parameters and other safety outcomes of brolocizumab treatment in patients with neovascular age-related macular degeneration.. <i>Pharmacology Research and Perspectives</i> , 2022 , 10, e00897	3.1	1
32	Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence. <i>Drug Discovery Today</i> , 2021 , 26, 2226-2231	8.8	2
31	Translational precision medicine: an industry perspective. <i>Journal of Translational Medicine</i> , 2021 , 19, 245	8.5	12
30	Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2595-2599	6.7	6
29	Systematic risk identification and assessment using a new risk map in pharmaceutical R&D. <i>Drug Discovery Today</i> , 2021 , 26, 2786-2793	8.8	1
28	Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial. <i>Cardiovascular Research</i> , 2021 , 117, 320-329	9.9	0
27	R&D efficiency of leading pharmaceutical companies - A 20-year analysis. <i>Drug Discovery Today</i> , 2021 , 26, 1784-1789	8.8	4
26	LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in obese adults with modest hypertriglyceridemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	2
25	A framework to guide dose & regimen strategy for clinical drug development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 1276-1280	4.5	1
24	The upside of being a digital pharma player. <i>Drug Discovery Today</i> , 2020 , 25, 1569-1574	8.8	23
23	Investigation and Management of Stool Frequency and Consistency Associated With SGLT1 Inhibition by Reducing Dietary Carbohydrate: A Randomized Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 995-1002	6.1	1
22	Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 802-814	6.1	3
21	Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?. <i>Journal of Translational Medicine</i> , 2018 , 16, 119	8.5	22
20	Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 1121-1130	2.8	1
19	Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017 , 42, 109-116	2.7	14
18	Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension. <i>Hypertension</i> , 2017 , 69, 32-41	8.5	55
17	Introduction to the Book 2016 , 1-9		

16	The Evolution of Clinical Development: From Technical Success to Clinical Value Creation 2016 , 202-223		
15	New Innovation Models in Pharmaceutical R&D 2016 , 400-415		1
14	A Review of the Pharmaceutical R&D Efficiency: Costs, Timelines, and Probabilities 2016 , 60-79		5
13	Changing R&D models in research-based pharmaceutical companies. <i>Journal of Translational Medicine</i> , 2016 , 14, 105	8.5	166
12	The effect of LCZ696 (sacubitril/valsartan) on amyloid- β concentrations in cerebrospinal fluid in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 878-90	3.8	68
11	Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 586-93	2.9	13
10	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1945-51	5.9	18
9	Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjects. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 45-51	2.9	8
8	Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid. <i>Thrombosis and Haemostasis</i> , 2006 , 95, 224-8	7	9
7	Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 37-44	2.9	24
6	Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 691-702	6.1	20
5	Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers. <i>Thrombosis and Haemostasis</i> , 2005 , 93, 794-795	7	7
4	Comparison of the initial hemodynamic effects of immediate-release versus sustained-release isosorbide-5-mononitrate following single oral doses. <i>Journal of Clinical Pharmacology</i> , 2000 , 40, 168-76	2.9	1
3	Comparison of the efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker mibefradil (50-100 mg) in mild to moderate hypertension. <i>Fundamental and Clinical Pharmacology</i> , 2000 , 14, 31-41	3.1	5
2	Role of renal nerves in the stimulation of the renin system by reduced renal arterial pressure. <i>Hypertension</i> , 1999 , 34, 1101-5	8.5	35
1	T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats. <i>British Journal of Pharmacology</i> , 1998 , 124, 579-85	8.6	33